Relapsed and refractory peripheral T-cell lymphoma
Showing 51 - 75 of >10,000
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma Trial in Worldwide (Valemetostat Tosylate)
Recruiting
- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma
- Valemetostat Tosylate
-
Duarte, California
- +59 more
Jun 3, 2022
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in London (Avelumab)
Completed
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
-
London, United KingdomUniversity College London Hospital
Oct 1, 2021
NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)
Not yet recruiting
- NK/T Cell Lymphoma Nos
- Brentuximab Vedotin in Combination with Tislelizumab
- (no location specified)
Apr 6, 2022
Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma Trial in Belgium, France (Brentuximab Vedotin -
Completed
- Refractory Peripheral T-Cell Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Brentuximab Vedotin - induction
- +3 more
-
Antwerpen, Belgium
- +38 more
Jan 9, 2023
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,
Completed
- T-Cell Lymphoma Relapsed
- +4 more
- IL-15 plus
- alemtuzumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022
Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)
Available
- Extranodal NK/T-cell Lymphoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 18, 2022
Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)
Active, not recruiting
- Lymphoma
- Relapsed/Refractory T-cell Lymphomas
- Romidepsin
- +2 more
-
Stanford, California
- +10 more
Feb 2, 2023
Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)
Completed
- Peripheral T Cell Lymphoma
- +18 more
-
Vancouver, British Columbia, Canada
- +29 more
Apr 29, 2022
Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +1 more
Jul 26, 2022
Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of
Recruiting
- Extranodal Natural Killer T Cell Lymphoma
- Tislelizumab combined with Liposomal mitoxantrone hydrochloride
- Maintenance of tislelizumab
-
Beijing, China
- +5 more
Jul 15, 2022
Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)
Not yet recruiting
- Hodgkin Lymphoma
- +7 more
- Anti CD30 CAR-T Cell Injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of medicine, Zhejiang Uni
Jan 12, 2022
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +20 more
- panobinostat
- +6 more
-
Scottsdale, Arizona
- +1 more
May 6, 2022
T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Italy (bone marrow
Recruiting
- T Acute Lymphoblastic Leukemia
- +3 more
- bone marrow and/or peripheral blood samples withdrawal
-
Ancona, Italy
- +9 more
Nov 24, 2022
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin
Active, not recruiting
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +16 more
- 6,8-bis(benzylthio)octanoic acid
- bendamustine hydrochloride
-
Winston-Salem, North Carolina
- +1 more
Apr 8, 2022
Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,
Active, not recruiting
- Relapsed Angioimmunoblastic T-Cell Lymphoma
- Refractory Angioimmunoblastic T-cell Lymphoma
- Oral azacitidine
- +3 more
-
Graz, Austria
- +33 more
Aug 24, 2022
T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in
Recruiting
- T Cell Non-Hodgkin Lymphoma
- +3 more
- AUTO4
-
Barcelona, Spain
- +4 more
Feb 1, 2022
Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Busulfan
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,
Not yet recruiting
- Acute Myelogenous Leukemia
- +17 more
- Peripheral Blood Stem Cell Transplant
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Mar 27, 2023
T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)
Recruiting
- T-cell Lymphomas
- NK-Cell Lymphomas
-
Miami, Florida
- +8 more
Aug 1, 2022
Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)
Terminated
- Hodgkin Lymphoma
- +2 more
- brentuximab vedotin
-
Anaheim, California
- +18 more
Dec 6, 2022
Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma Trial in
Recruiting
- Natural Killer/T-cell Lymphoma
- +2 more
-
Seoul, Kangnamgu, Korea, Republic ofSamsung Medical Center
Sep 22, 2021
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022
